by Garth Sundem | Dec 4, 2019 | Featured, Research
Martin McCarter, MD, and colleagues target myeloid-derived suppressor cells in melanoma In melanoma, myeloid-derived suppressor cells (MDSCs) are bad – the more MDSCs, the poorer a patient’s prognosis. That’s because when these MDSCs expand to accumulate near melanoma...
by Garth Sundem | Dec 2, 2019 | Featured, Research
When prostate cancer spreads, it most often spreads to bone. And while the 5-year survival rate for prostate cancer that has not spread is nearly 100 percent, once the disease reaches bone, the 5-year survival rate is only 29 percent. Now a University of Colorado...
by Garth Sundem | Nov 19, 2019 | Featured, Research
Cathy J. Bradley, PhD Genetically targeted drugs and immunotherapies are transforming the way we treat many forms of lung cancer. However, a University of Colorado Cancer Center study published in the Journal of the National Cancer Institute shows that while the use...
by Garth Sundem | Nov 6, 2019 | Featured, Research
Richard Schulick, MD, MBA On Tuesday, November 5, University of Colorado Cancer Center members met to present cutting-edge research taking place in labs and clinics across CU Cancer Center consortium partners, including CU Anschutz, CU Boulder, CSU Flint Animal Cancer...
by Taylor Abarca | Oct 9, 2019 | Featured, Honors, Research
Tejas Patil, MD University of Colorado Cancer Center member, Tejas Patil, MD, received the John Fisher Legacy Fellowship Award at the International Association for the Study of Lung Cancer (IASLC) World Conference held in Barcelona last month. Patil is the first...
by Garth Sundem | Oct 8, 2019 | Featured, Research
Manali Kamdar, MD With improved treatments, especially the use of anti-cancer immunotherapies, more than two-thirds of all patients diagnosed with diffuse large B-cell lymphoma (DLBCL) will survive. However, after treatment, patients are at a small but real risk of...
